Five numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 12 other studies
the abstract, start to end
… group, and 100 in the placebo group (HR 1.04; 95% CI 0.79-1.36).
… vs. atorvastatin [30] (CV outcome HR 1.25; 95% CI 1.14-2.19; all-cause …
… for all outcomes (all-cause death RR 2.52, 95% CI 0.65-9.74; CV deaths …
… of E+simvastatin for allcause death (RR 1.02, 95% CI 0.95-1.09) and SAEs (RR …
… reduction of the risk of CV death (RR 0.93, 95% CI 0.80-1.07; and 0.83, …
← favours treatmentfavours comparator →
could be chanceAll-cause mortality
HR 1.040.79–1.36
All-cause mortality
HR 1.251.14–2.19
All-cause mortality
RR 2.520.65–9.74
Cardiovascular events
RR 1.020.95–1.09
All-cause mortality
RR 0.930.80–1.07
StatinsOther lipid agentsCardiovascular eventsAll-cause mortality
Statins × all-cause mortalityhelps?mixed
unlikelylikely
0.50not counted
Other lipid agents × all-cause mortalityhelps?one trial
unlikelylikely
0.50not counted
Statins × cardiovascular eventshelps?replicated
unlikelylikely
0.86not counted
← favours treatmentfavours comparator →
1 / 5